文献速递心力衰竭与心肌病心律失常血脂与心血管预防

精英运动员遗传性心脏病返场竞技的结局分析

Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该多中心回顾性研究纳入76例确诊遗传性心脏病的精英运动员(66%一级联盟,34%职业),72%最初被取消资格但经综合评估与共享决策后选择无限制返场。平均随访7±6年,仅发生1例运动相关(1.3%)和2例非运动相关不良心脏事件,无死亡。

要点

  • 精英运动员确诊遗传性心脏病后经评估与共享决策返场,不良事件率低。
  • 平均随访7±6年,仅1例运动相关(1.3%)和2例非运动相关事件。
  • 随访期间无死亡,提示返场策略需个体化评估。

核心结论

  • 经仔细评估、风险分层和个体化治疗后,共享决策下的返场与精英运动员低非致命事件率相关。

研究设计与样本

  • 多中心回顾性分析,纳入76例确诊遗传性心脏病的精英运动员,年龄19.9±5岁,28%女性。

主要发现

  • 66%为一级联盟运动员,34%为职业运动员;53%为肥厚型心肌病,26%为长QT综合征。
  • 63%(48/76)诊断前无症状,经赛前心血管筛查发现。
  • 72%(55/76)最初被取消资格,后经综合评估和共享决策选择无限制返场。
  • 平均随访7±6年,仅1例运动相关(1.3%)和2例非运动相关不良心脏事件,无死亡。

临床怎么用

  • 对精英遗传性心脏病运动员,在综合评估、风险分层和个体化治疗后,可考虑共享决策下的返场。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People diagnosed with genetic heart diseases (GHDs) associated with sudden cardiac death (SCD) have historically been restricted from competitive sports. Recent data documenting return-to-play (RTP) experiences following shared decision making (SDM) suggest that cardiac event rates for athletes with a GHD are lower than previously described, thereby suggesting an opportunity to reconsider this paradigm. OBJECTIVES: The purpose of this study was to evaluate clinical outcomes among National Collegiate Athletic Association Division I university and professional athletes diagnosed with a GHD. METHODS: A multicenter retrospective analysis was performed to examine demographics, clinical characteristics, RTP outcomes, and cardiac events among elite athletes with a GHD. RESULTS: A total of 76 elite (66%, Division I, 34% professional) athletes (age 19.9 ± 5 years, 28% women) diagnosed with a GHD (hypertrophic cardiomyopathy [53%], long QT syndrome, long QT syndrome [26%]) comprise this cohort. Most athletes were asymptomatic (48 of 76, 63%) before diagnosis and had their GHD detected during routine preparticipation cardiovascular screening. Most athletes (55 of 76, 72%) were initially disqualified from their sport but subsequently opted for unrestricted RTP after comprehensive clinical evaluation and SDM. To date, (mean follow-up 7 ± 6 years), only 1 exercise-related (1.3%) and 2 nonexercise-related GHD-associated adverse cardiac events occurred. There have been no fatalities during follow-up. CONCLUSIONS: This is the first study describing the experience of athletes with a known SCD-predisposing GHD who are competing at the elite level. After careful evaluation, risk stratification, and tailoring of their GHD therapy, RTP following SDM appears associated with low, nonfatal events rates at elite levels of sport.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Martinez KA, Bos JM, Baggish AL, et al. Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death. J Am Coll Cardiol. 2023. PMID: 37587576. doi:10.1016/j.jacc.2023.05.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。